Protalix BioTherapeutics Files 8-K Report
Ticker: PLX · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, disclosure
Related Tickers: PLX
TL;DR
PLX filed an 8-K, "Other Events" – need more info.
AI Summary
On August 1, 2025, Protalix BioTherapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding transactions, agreements, or financial figures were provided in the excerpt.
Why It Matters
This filing signals a material event has occurred for Protalix BioTherapeutics, Inc., requiring public disclosure. Investors should monitor for further details to understand the event's impact.
Risk Assessment
Risk Level: low — The filing itself is a standard disclosure and does not contain information that inherently increases risk; further details are needed to assess specific risks.
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Registrant
- August 1, 2025 (date) — Date of Report
FAQ
What specific event triggered the "Other Events" disclosure in the 8-K filing?
The provided excerpt of the 8-K filing does not specify the nature of the "Other Events" that triggered the disclosure.
When was this 8-K report filed by Protalix BioTherapeutics, Inc.?
The report was filed on August 1, 2025.
What is the Commission File Number for Protalix BioTherapeutics, Inc.?
The Commission File Number for Protalix BioTherapeutics, Inc. is 001-33357.
Where is Protalix BioTherapeutics, Inc. headquartered?
Protalix BioTherapeutics, Inc. is located at 2 University Plaza, Suite 100, Hackensack, NJ 07601.
What is the Standard Industrial Classification code for Protalix BioTherapeutics, Inc.?
The Standard Industrial Classification code for Protalix BioTherapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 regarding Protalix BioTherapeutics, Inc. (PLX).